Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Highlights the need for rebuilding, restructuring, and re-imagining resilient healthcare systems in India
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
It paves the way for an industry Code of Good Practice
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Subscribe To Our Newsletter & Stay Updated
